Market capitalization | $120.79b |
Enterprise Value | $115.93b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 11.23 |
P/S ratio (TTM) P/S ratio | 11.70 |
P/B ratio (TTM) P/B ratio | 8.17 |
Revenue growth (TTM) Revenue growth | 10.32% |
Revenue (TTM) Revenue | $10.32b |
Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
35 Analysts have issued a Vertex Pharmaceuticals forecast:
35 Analysts have issued a Vertex Pharmaceuticals forecast:
Jun '24 |
+/-
%
|
||
Revenue | 10,323 10,323 |
10%
10%
|
|
Gross Profit | 8,922 8,922 |
9%
9%
|
|
EBITDA | -182 -182 |
105%
105%
|
EBIT (Operating Income) EBIT | -391 -391 |
110%
110%
|
Net Profit | -490 -490 |
115%
115%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Head office | United States |
CEO | Reshma Kewalramani |
Employees | 5,400 |
Founded | 1989 |
Website | www.vrtx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.